Fletcher SA, Cole AP, Lu C, et al. - Using the Surveillance, Epidemiology, and End Results registry and the National Cancer Data Base, researchers analyzed people younger than 65 years who received a diagnosis of bladder cancer from 2007 to 2014, to determine the influence of a patient's insurance status (privately insured, insured by Medicaid, or uninsured) on the outcomes [diagnosis with advanced disease, cancer-specific survival, delay in treatment longer than 90 days, treatment in a high-volume hospital, and receipt of neoadjuvant chemotherapy] in bladder cancer, given health insurance remains a key mediator of healthcare disparities. The likelihood of receiving a diagnosis of muscle-invasive bladder cancer was nearly twice among uninsured and Medicaid-insured people vs those with private insurance. For uninsured and Medicaid-insured people vs the privately insured, delays in treatment longer than 90 days were more likely. Overall, worse prognoses and poorer care quality were reported among uninsured and Medicaid-insured people vs privately insured people. A decreased burden of this disease may be ensured by extending high-quality insurance coverage to marginalized populations.